Elanco Animal Health Incorporated (ELAN): Company Overview and Market Position
Elanco Animal Health Incorporated (ELAN) is a global leader in the animal health industry, dedicated to innovating, developing, manufacturing, and marketing products for pets and farm animals worldwide. As the second largest independent animal health company, Elanco operates in a growing market driven by increasing demand for protein and rising pet ownership.
Core Business and Product Portfolio
Elanco’s business spans critical areas of animal health, including parasiticides, vaccines, and therapeutics. For companion animals, the company offers well-known brands such as Seresto, K-9 Advantage, Advantix, and Advocate for flea and tick prevention. Its prescription parasiticide portfolio includes the Credelio Family, Interceptor Plus, and Drontal lines. Elanco also provides a differentiated vaccines portfolio covering major pet health risks and therapeutics for pain, otitis, cardiovascular, dermatology, and osteoarthritis conditions in dogs and cats, notably under the Galliprant trademark.
In the farm animal sector, Elanco delivers solutions focused on improving food safety, quality, affordability, and sustainability through products that enhance animal well-being and productivity.
Financial Performance and Stock Information
As of the close of trading on April 16, 2026, Elanco Animal Health Incorporated (ELAN) stock was priced at $23.13, reflecting a daily decrease of $0.10 (-0.43%). The stock’s 52-week trading range spans from $8.33 to $27.72, with a year-to-date gain of 2.21% and a one-year return of 185.56%. The company’s intraday market capitalization stood at approximately $11.551 billion.
Elanco does not currently report a trailing price-to-earnings (P/E) ratio due to negative earnings per share (EPS) on a trailing twelve-month basis, which was recorded at -$0.47. The company’s beta (5-year monthly) is 1.88, indicating higher volatility relative to the overall market.
Recent Developments and Investor Relations
Elanco is advancing its late-stage pipeline with potential blockbuster products targeting large market opportunities. The company scheduled a webcast for May 6, 2026, to detail its first-quarter financial results. Investors and stakeholders can access updates, press releases, and filings through Elanco’s official investor relations portal at investor.elanco.com.
The company maintains an active investor relations team, including Tiffany Kanaga and Beth Haney, accessible via email at investor@elanco.com for inquiries and email alert subscriptions.
Market Context and Industry Standing
Operating in the specialty and generic drug manufacturers segment within healthcare, Elanco competes in a dynamic industry where innovation and regulatory compliance are critical. The company emphasizes its role in addressing global challenges related to animal protein supply and companion animal health, aligning its strategy with trends in sustainability and technological advancement in veterinary medicine.
Data reflects trading information and company details available as of April 17, 2026. Stock prices are subject to change. For real-time quotes and official disclosures, refer to the New York Stock Exchange (NYSE) and Elanco’s investor relations communications.